CEACAM5 and colorectal carcinoma: In the analysis that included stage II CRC with elevated preoperative CEA only, the 3-year RFS was 71.4% (65.5%-77.9%) vs. 80.5% (77.7%-83.5%) in patients with elevated vs. normal CA19-9 (unadjusted HR: 1.58, 95% CI: 1.19–2.11, P < 0.001) (Supplementary Figure S6a).